相关实验视频

Updated: Jan 10, 2026

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8⁺ T Cells During LN Metastasis

Published on: January 26, 2024

向瘤排水淋巴结以克服对癌症免疫疗法的抵抗力:一个更新

Jianan Lu¹, Jiangnan Yu¹, Tuo Xu^2,1

¹These authors contributed equally.

Cancer drug resistance (Alhambra, Calif.)

|November 24, 2025

概括

免疫检查点抑制剂 (ICI) 耐药性与T细胞功能障碍有关. 向瘤排水淋巴结 (TDLNs) 可以恢复免疫功能并改善癌症治疗结果.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
细胞生物学细胞生物学

背景情况:

免疫检查点抑制剂 (ICI) 耐药性是一个重大的临床挑战.
内T细胞功能障碍是ICI耐药性的关键驱动因素.
瘤排水淋巴结 (TDLNs) 在启动和调节抗瘤免疫反应方面发挥着至关重要的作用.

研究的目的:

审查ICI耐药性的瘤内在和TDLN中心机制.
总结TDLN针对的克服ICI抵抗的策略.
突出TDLNs作为改善ICI疗效的治疗目标的潜力.

主要方法:

关于ICI耐药机制的当前文献的综述.
对导致免疫功能障碍的TDLN特异性缺陷的分析.
新兴的TDLN向治疗策略的摘要.

主要成果:

在TDLNs的缺陷,包括损害树突细胞迁移和免疫抑制,导致系统性免疫功能障碍和ICI耐药性.
针对TDLN的策略包括重塑免疫抑制微环境,扩大原始耗尽的T (Tpex) 细胞,并利用TDLN衍生的Tpex细胞进行采用性细胞疗法.
将TDLN重新定位为治疗目标提供了一种有希望的方法来克服ICI抵抗.

结论:

TDLN对免疫反应至关重要,是克服ICI耐药性的关键目标.
专注于TDLNs的治疗策略可以恢复有效的抗原呈现并增强抗瘤免疫力.
准TDLN有可能改善ICI耐药患者的临床结果.

关键词:

免疫检查点抑制剂免疫检查点抑制剂免疫疗法耐药性免疫疗法耐药性瘤微环境是一个微环境.瘤排水淋巴结的淋巴结.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...